1. Monash Health
  2. Monash Health research
  3. Articles
Please use this identifier to cite or link to this item: https://repository.monashhealth.org/monashhealthjspui/handle/1/34904
Full metadata record
DC FieldValueLanguage
dc.contributor.authorLeidner R.en
dc.contributor.authorSim F.en
dc.contributor.authorBell R.B.en
dc.date.accessioned2021-05-14T11:47:06Zen
dc.date.available2021-05-14T11:47:06Zen
dc.date.copyright2019en
dc.date.created20190405en
dc.date.issued2019-04-05en
dc.identifier.citationOral and maxillofacial surgery clinics of North America. 31 (1) (pp 85-100), 2019. Date of Publication: 01 Feb 2019.en
dc.identifier.issn1558-1365 (electronic)en
dc.identifier.urihttps://repository.monashhealth.org/monashhealthjspui/handle/1/34904en
dc.description.abstractThe immune system has a vital role in the development, establishment, and progression of head and neck squamous cell carcinoma (HNSCC). Immune evasion of cancer cells leads to progression of HNSCC. An understanding of this mechanism provides the basis for improved therapies and outcomes for patients. Through the tumor's influence on the microenvironment, the immune system can be exploited to promote metastasis, angiogenesis, and growth. This article provides an overview of the interaction between immune infiltrating cells in the tumor microenvironment, and the immunologic principles related to HNSCC. Current immunotherapeutic strategies and emerging results from ongoing clinical trials are presented.Copyright © 2018 Elsevier Inc. All rights reserved.en
dc.languageEnglishen
dc.languageenen
dc.publisherNLM (Medline)en
dc.titleImmunotherapy for Head and Neck Cancer.en
dc.typeReviewen
dc.identifier.doihttp://monash.idm.oclc.org/login?url=http://dx.doi.org/10.1016/j.coms.2018.09.002en
dc.publisher.placeUnited Statesen
dc.identifier.pubmedid30449528 [http://www.ncbi.nlm.nih.gov/pubmed/?term=30449528]en
dc.identifier.source625025173en
dc.identifier.institution(Sim) Department of Oral and Maxillofacial Surgery, The Royal Melbourne Hospital, 300 Grattan Street, Parkville, Victoria 3050, Australia; Department of Oral and Maxillofacial Surgery, Monash Health, 823 Centre Road, Bentleigh East, Victoria 3165, Australia; Oral and Maxillofacial Surgery Unit, Barwon Health, Ryrie Street & Bellerine Street, Geelong, Victoria 3220, Australia (Leidner) Earle A. Chiles Research Institute, Robert W. Franz Cancer Center, Providence Portland Medical Center, 4805 Northeast Glisan Street, Portland, OR 97213, United States (Bell) Earle A. Chiles Research Institute, Robert W. Franz Cancer Center, Providence Portland Medical Center, Providence Cancer Institute, 4805 Northeast Glisan Street, Suite 2N35, Portland, OR 97213, USA; Head and Neck Institute, 1849 NW Kearney, Suite 300, Portland, Oregon 97209, USAen
dc.rights.statementThis record is sourced from MEDLINE/PubMed, a database of the U.S. National Library of Medicineen
dc.subect.keywordsAdoptive T-cell transfer Checkpoint inhibitor Head and neck cancer Immunotherapy Oncolytic virus Squamous cell carcinomaen
dc.identifier.authoremailBell R.B.; richard.bell@providence.orgen
item.fulltextNo Fulltext-
item.cerifentitytypePublications-
item.grantfulltextnone-
item.openairetypeReview-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
Appears in Collections:Articles
Show simple item record

Page view(s)

14
checked on Sep 29, 2024

Google ScholarTM

Check


Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.